Semax: Molecular Profile & the Mechanisms Researchers Have Studied

What Semax is — a synthetic ACTH(4-10) analog

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a synthetic analog of the ACTH(4-7) core within the ACTH(4-10) melanocortin fragment, extended at the C-terminus with a Pro-Gly-Pro tripeptide. The ACTH(4-10) fragment was of interest to researchers because it retained central-nervous-system-relevant properties of adrenocorticotropic hormone that could be studied separately from its hormonal and endocrine axis. This is a molecule-properties description; it makes no claim that Semax “does” anything in humans.

Sequence and the Pro-Gly-Pro extension

The C-terminal Pro-Gly-Pro is described in the literature as contributing proteolytic resistance and steric hindrance against peptidase cleavage relative to the parent fragment — a molecular-stability property. Pro-Gly-Pro has itself been studied as a fragment (Dergunova et al.), which is why the extension is named specifically rather than treated as inert. These are structural and biochemical facts only.

Origin — the Institute of Molecular Genetics

Semax was developed in the 1980s, in work attributed to Myasoedov and Ashmarin, at the Institute of Molecular Genetics of the Russian Academy of Sciences (with Moscow State University), out of the melanocortin/ACTH-fragment research line. That development history is relevant background; for the Selank contrast that shares this lab lineage, see the sibling comparison page rather than a re-explanation here.

Mechanisms researchers have examined

The mechanism literature is best read pathway by pathway, with every finding framed as what a given study measured in a given model.

BDNF and TrkB neurotrophic signaling

This is the most-cited mechanism. Rat-hippocampus work in the Shadrina/Dolotov line (Brain Research, 2006) reported Semax-associated changes in BDNF protein and trkB, and increases in exon-III BDNF and trkB mRNA; Dolotov et al. (J Neurochem, 2006) reported specific binding and elevated BDNF protein in rat basal forebrain. Temporal-dynamics gene-expression studies (2008; 2009) examined BDNF and NGF expression across hippocampus, frontal cortex and retina. Presented as study facts: for example, a single 50 µg/kg application was reported to raise hippocampal BDNF roughly 1.4-fold — a figure describing what that study administered to its animal model, not a human dose or a benefit. The recurring keywords here — semax BDNF, semax neurotrophic — name the pathway most examined.

Dopaminergic and serotonergic systems

Eremin et al. (Neurochemical Research, 2005) reported activation of dopaminergic and serotonergic systems and changes in monoamine turnover in rodents on a rapid, roughly 30-minute timescale — faster than neurotrophin transcription, which the researchers noted suggests a distinct mechanism. This is mechanism-under-study framing only.

Neuroprotection and neuroinflammation in ischemia models

Preclinical cerebral ischemia-reperfusion work (Dergunova et al., Semax and Pro-Gly-Pro, PMC 2024) examined transcription of neurotrophins and their receptors and the suppression of pro-inflammatory transcripts (IL-1α/β, IL-6, chemokines). Semax is a registered drug in Russia used there in acute ischemic-stroke neurology, and Russian clinical reports exist (Gusev & Skvortsova, Zhurnal Nevrologii i Psikhiatrii, 1997; Gusev, Martynov et al., 2018) that examined biochemical markers, plasma BDNF and functional scales. Those studies are described here as what they looked at — there is human clinical literature, it is Russian, and it is context — not a benefit a reader should expect.

Research models used in the literature

The study systems, summarised neutrally to help a researcher judge translational scope: rodents (rat hippocampus, frontal cortex, basal forebrain and retina), glial cell cultures, ischemia-reperfusion models, and Russian clinical cohorts. Most of the mechanistic data is preclinical and animal-based.

A note on the evidence base — much of it is Russian-published

Stated plainly: a large share of Semax research was conducted and published in Russian-language journals (for example Zhurnal Nevrologii i Psikhiatrii and Molekulyarnaya Genetika), some of it pre-dating modern reporting standards; independent Western replication is limited, and much of the mechanistic work is preclinical. This is offered as provenance and study-stage information so a reader can weigh the literature critically — not as a judgement that the work is “weak” or that any benefit is “unproven.” Provenance and stage, stated factually.

Semax vs. Selank — where to compare

Semax and Selank are often discussed together as Russian-developed nootropic-research peptides with different parent molecules and different mechanisms studied. For the side-by-side, see the sibling comparison Semax vs Selank; for Selank’s own literature, see Selank research. This page does not restate the comparison content.

Research-grade sourcing, COA and verification

For nootropic-research peptides especially, the useful literature is specific to a precisely-made sequence, so compound identity and purity matter for reproducible research: per-batch third-party COA, HPLC purity and mass-spec identity, and lot verification. Check the exact batch on the self-serve verify tool, see how to read a COA, and view specifications on the Semax 11 mg product page. Sourcing and quality are explicitly permitted content.

Frequently asked questions

Literature cited

1. Dolotov OV, et al. “Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of BDNF protein in rat basal forebrain.” Journal of Neurochemistry. 2006.
2. Shadrina M / Dolotov OV, et al. “Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Research. 2006.
3. Eremin KO, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005.
4. Agapova / Shadrina, et al. “Temporal dynamics of BDNF and NGF gene expression in rat hippocampus, frontal cortex, and retina under Semax action.” 2008; 2009 (PubMed 18756821, 19662538; Russian journals).
5. Dergunova LV, et al. “Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.” 2024 (PMC).
6. Gusev EI, Skvortsova VI, et al. Clinical/electrophysiological study of Semax in acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii. 1997 (Russian).
7. Gusev EI, Martynov MYu, et al. “Efficacy of Semax in patients at different stages of ischemic stroke.” Zhurnal Nevrologii i Psikhiatrii. 2018 (PubMed 29798983; Russian).
8. Historical / development: Myasoedov NF, Ashmarin IP — Institute of Molecular Genetics, Russian Academy of Sciences (1980s).